BCR-ABL point mutants isolated from patients with imatinib mesylate–resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone …
ME Gorre, K Ellwood-Yen, G Chiosis… - Blood, The Journal …, 2002 - ashpublications.org
Clinical resistance to imatinib mesylate is commonly observed in patients with advanced
Philadelphia chromosome–positive (Ph+) leukemias. Acquired resistance is typically …
Philadelphia chromosome–positive (Ph+) leukemias. Acquired resistance is typically …
Factors associated with tyrosine kinase inhibitor initiation and adherence among Medicare beneficiaries with chronic myeloid leukemia
Purpose There is substantial concern surrounding affordability of orally administered
anticancer therapies, particularly for Medicare beneficiaries. We examined rates of initiation …
anticancer therapies, particularly for Medicare beneficiaries. We examined rates of initiation …
Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem …
L Nilsson, I Åstrand-Grundström… - Blood, The Journal …, 2000 - ashpublications.org
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal disorders
characterized by ineffective hematopoiesis and frequent progression to acute myeloid …
characterized by ineffective hematopoiesis and frequent progression to acute myeloid …
Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients
L Valeyrie, S Bastuji-Garin, J Revuz, N Bachot… - Journal of the American …, 2003 - Elsevier
Background: Imatinib is a new major treatment in chronic myeloid leukemia. Objective: To
study the cutaneous reactions induced by imatinib. Methods: All inpatients and outpatients …
study the cutaneous reactions induced by imatinib. Methods: All inpatients and outpatients …
The biology and therapy of adult acute lymphoblastic leukemia
S Faderl, S Jeha, HM Kantarjian - … International Journal of the …, 2003 - Wiley Online Library
BACKGROUND Much progress has been made in understanding the biology of acute
lymphoblastic leukemia (ALL). This has translated into the recognition of several subgroups …
lymphoblastic leukemia (ALL). This has translated into the recognition of several subgroups …
Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy
Y Choi, K Jung - Experimental & Molecular Medicine, 2023 - nature.com
Solid tumors are complex entities that actively shape their microenvironment to create a
supportive environment for their own growth. Angiogenesis and immune suppression are …
supportive environment for their own growth. Angiogenesis and immune suppression are …
The paradox of arsenic: molecular mechanisms of cell transformation and chemotherapeutic effects
AM Bode, Z Dong - Critical reviews in oncology/hematology, 2002 - Elsevier
Arsenic is a well-documented carcinogen that also appears to be a valuable therapeutic tool
in cancer treatment. This creates a paradox for which no unified hypothesis has been …
in cancer treatment. This creates a paradox for which no unified hypothesis has been …
Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl–positive cells
JT Thiesing, S Ohno-Jones… - Blood, The Journal of …, 2000 - ashpublications.org
Chronic myelogenous leukemia (CML), a malignancy of a hematopoietic stem cell, is
caused by the Bcr-Abl tyrosine kinase. STI571 (formerly CGP 57148B), an Abl tyrosine …
caused by the Bcr-Abl tyrosine kinase. STI571 (formerly CGP 57148B), an Abl tyrosine …
AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia
M Golemovic, S Verstovsek, F Giles, J Cortes… - Clinical cancer …, 2005 - AACR
Resistance to or intolerance of imatinib in patients with Philadelphia chromosome–positive
chronic myelogenous leukemia (CML) has encouraged the development of more potent Bcr …
chronic myelogenous leukemia (CML) has encouraged the development of more potent Bcr …
Ophthalmic manifestations of leukemia
KE Talcott, RJ Garg, SJ Garg - Current opinion in ophthalmology, 2016 - journals.lww.com
Patients with leukemia often have ocular manifestations. These occur either from direct
infiltration of neoplastic cells or from indirect or secondary causes, including hematologic …
infiltration of neoplastic cells or from indirect or secondary causes, including hematologic …